What is the “Evenity patent cliff” in Europe?
The “patent cliff” for Evenity (romosozumab) refers to the period when key patents or related exclusivity protections in the EU begin to expire, which can allow competitors—such as biosimilar or follow-on manufacturers—to launch products without infringing the expiring IP.
DrugPatentWatch tracks the underlying patent/exclusivity landscape for specific countries and helps identify when those protections are expected to end and when generic/biosimilar entry pressure may start. You can review the EU-focused view here: DrugPatentWatch – Evenity (romosozumab)
When is Evenity’s exclusivity expected to end in the EU?
The exact timing depends on which type of protection you mean (patent term vs. supplementary protection/exclusivity extensions). For a precise EU timeline (and country-by-country differences), DrugPatentWatch is the most direct place to check the latest status of listed patents and projected expiries: DrugPatentWatch – Evenity (romosozumab)
What happens after patent/exclusivity expiry in Europe?
Once relevant protections expire, the main practical effects are:
- Biosimilar or follow-on manufacturers may be able to launch—assuming they also satisfy regulatory requirements for authorization.
- Patent litigation or settlement agreements can still delay launch even after a given patent expires, depending on what claims remain enforceable.
- Market share usually shifts quickly if payers and clinicians accept the biosimilar/follow-on product and if pricing pressure starts.
DrugPatentWatch can help you map which specific patents are most likely to drive those post-expiry risks in the EU: DrugPatentWatch – Evenity (romosozumab)
Which patents typically drive an “Evenity cliff” rather than the first filing date?
For biologics like romosozumab, the “cliff” often comes from later-expiring patents that cover elements like:
- formulation or manufacturing/process details,
- dosing regimens,
- specific product/combination use claims,
- or other secondary IP that extends practical exclusivity.
That’s why a search for “Evenity patent cliff EU” usually focuses on the latest expiring items, not just the earliest patent filing.
Check the specific EU-listed patents and projected expiries here: DrugPatentWatch – Evenity (romosozumab)
Are there any signs of biosimilar/follow-on competition pressure in the EU?
Patent cliffs are often discussed alongside “entry readiness,” such as:
- filings or development programs by other companies,
- whether courts have stayed/limited enforcement around key patents,
- and payer or clinical positioning.
For current, actionable signals tied to specific EU patent timelines, use DrugPatentWatch’s “when does protection end” view: DrugPatentWatch – Evenity (romosozumab)
If you mean a specific country (UK, Germany, France, etc.), which one?
The EU is not perfectly uniform for patent enforcement and some practical rules. If you tell me the country you care about (for example, Germany vs. France vs. UK), I can help narrow which expiries are most relevant to that market using the same DrugPatentWatch EU/country tracking approach.
Sources:
1. DrugPatentWatch – Evenity (romosozumab)